经尿道膀胱肿瘤电切术联合吡柔比星膀胱灌注治疗对浅表性膀胱癌患者预后及血清相关因子的影响

Effect of TRUBt Combined with Pirarubicin Bladder Perfusion Therapy on Prognosis of Superficial Bladder Cancer and Serum Related Factors

目的探究经尿道膀胱肿瘤电切术(TURBt)联合吡柔比星灌注治疗对浅表性膀胱癌患者的预后及对血清相关因子的影响。方法对120例浅表性膀胱癌患者按照入院时间顺序随机分为对照组与观察组,对照组接受单纯TURBt治疗,观察组接受TURBt联合吡柔比星灌注治疗。比较2组患者术后复发率、血清肿瘤相关因子、并发症。结果观察组术后1年复发率为5.0%,明显低于对照组,P<0.05。观察组平均复发时间明显低于对照组,P<0.05。观察组血清中VEGF、FGF、MMP-s水平均明显低于对照组,P<0.05。2组患者术后并发症发生率无明显统计学差异,P>0.05。结论 TRUBt联合吡柔比星灌注治疗浅表性膀胱癌可以降低术后复发率,同时改善恶性肿瘤相关血清因子水平,且无明显不良反应,值得临床推广。

Objective To explore the effect of TRUBt combined with pirarubicin bladder perfusion therapy on prognosis of superficial bladder cancer and serum related factors. Methods A total of 120 patients with superficial bladder cancer were randomly divided into 2 groups,the control group received TURBt treatment,and the observation group received TURBt combined with pirarubicin bladder perfusion therapy. The recurrence rate,serum tumor related factors and complications were compared between the 2 groups. Results 1-year recurrence rate of the observation group after the surgery was 5. 0%,which was significantly lower than that of the control group,P〈0. 05. The average recurrence time of the observation group was significantly lower than that of the control group,P〈0. 05. The serum level of VEGF,FGF,and MMP-s in the observation group were significantly lower than that of the control group,P〈0. 05. There was no significant difference in the incidence of postoperative complications between the 2 groups,P〈0. 05. Conclusion TRUBt combined with the pirarubicin bladder perfusion therapy treatment on superficial bladder cancer can reduce the recurrence rate,improve the level of serum factors without obvious adverse reactions,it is worthy of clinical promotion.